Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
psychedelic drug
Biotech
Definium hits another ph. 3 homerun with anxiety ‘sea change’
The 214-patient Voyage trial pitted a psychoactive session with Definium’s DT120 ODT against placebo, with the psychedelic coming out ahead.
Darren Incorvaia
Aug 12, 2026 7:00am
Jupiter enters psychedelics space with $100M deal for MDMA drug
Jul 21, 2026 10:00am
Why other Big Pharmas could follow Lilly into psychedelics
Jul 20, 2026 4:00am
Lilly inks $2.8B AtaiBeckley psychedelic buyout to challenge J&J
Jul 16, 2026 7:32am
Definium’s LSD depression drug produces ‘best ever’ ph. 3 data
Jun 22, 2026 7:00am
‘Real momentum’ or ‘absurd’? Trump stance shakes up psychedelics
May 4, 2026 3:30am
